Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Opioid To-Do List Could Redefine Pain Market For Brands, Generics

Executive Summary

Supporters of narrowing opioid drugs’ non-cancer pain indication tell FDA that pain patients often suffer the consequences of addiction and misuse.

You may also be interested in...



Purdue Petition Seeks FDA Commitment To “Adapted” Studies For OxyContin Generics

Company says a generic should be equivalent or better than reformulated OxyContin on all the tests to ensure it has equivalent abuse-deterrent capabilities.

FDA’s Parks Expands REMS Portfolio With Move To ODE II Deputy Slot

Currently the head of the Division of Metabolic and Endocrinology Products, Parks has handled drug safety controversies in diabetes and obesity products.

Strategy Of A Corporate Split: An Interview With Mallinckrodt’s Mark Trudeau and Matt Harbaugh

CEO-designate and CFO for the Mallinckrodt specialty pharma spin-out from Covidien discuss the strategy for differentiating its products in a competitive analgesic space. Despite a goal of becoming a leading specialty pharma, the new company does not plan to divest its imaging or active pharmaceutical ingredient businesses.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS055124

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel